Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The 40S ribosomal protein S6 kinase-1 (S6K1) is a crucial downstream effector of the PI3K/AKT/mTOR pathway. S6K1 overexpression is found in 10% to 30% of breast cancers and is associated with aggressive disease and poor prognosis. Herein, we investigated the relationship between the expression of phosphorylated S6K1 (p-S6K1) and efficacy of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Methods: We retrospectively analyzed the data of 36 patients with HER2-positive metastatic breast cancer treated with lapatinib between January 2010 and September 2014. The p-S6K1 expression status of the primary tumor was assessed via immunohistochemistry using a mouse monoclonal antibody. Results: Fourteen of the 36 patients (38.9%) had p-S6K1-positive tumors. The median progression-free survival (PFS) of patients with p-S6K1-positive tumors was significantly longer than that of patients with p-S6K1-negative tumors (13.4 months vs. 7.1 months, p=0.025). In multivariate analysis, p-S6K1 positivity remained an independent, favorable predictive factor for PFS (hazard ratio, 0.32; 95% confidence interval, 0.11–0.97; p=0.044). Conclusion: The high expression of p-S6K1 was significantly associated with prolonged PFS, suggesting that p-S6K1 can be a potential biomarker for predicting the efficacy of lapatinib in patients with HER2-positive metastatic breast cancer.
Abstract
Purpose: The 40S ribosomal protein S6 kinase-1 (S6K1) is a crucial downstream effector of the PI3K/AKT/mTOR pathway. S6K1 overexpression is found in 10% to 30% of breast cancers and is associated with aggressive disease and poor prognosis. Herein, we investigated the relationship between the expression of phosphorylated S6K1 (p-S6K1) and efficacy of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Methods: We retrospectively analyzed the data of 36 patients with HER2-positive metastatic breast cancer treated with lapatinib between January 2010 and September 2014. The p-S6K1 expression status of the primary tumor was assessed via immunohistochemistry using a mouse monoclonal antibody. Results: Fourteen of the 36 patients (38.9%) had p-S6K1-positive tumors. The median progression-free survival (PFS) of patients with p-S6K1-positive tumors was significantly longer than that of patients with p-S6K1-negative tumors (13.4 months vs. 7.1 months, p=0.025). In multivariate analysis, p-S6K1 positivity remained an independent, favorable predictive factor for PFS (hazard ratio, 0.32; 95% confidence interval, 0.11–0.97; p=0.044). Conclusion: The high expression of p-S6K1 was significantly associated with prolonged PFS, suggesting that p-S6K1 can be a potential biomarker for predicting the efficacy of lapatinib in patients with HER2-positive metastatic breast cancer.
참고문헌 (30)
- Slamon DJ, "Studies of the HER-2", neu proto-oncogene in human breast and ovarian cancer, 1989, pp.244, 707~712
- Yarden Y, "Untangling the ErbB signalling network", Nat Rev Mol Cell Biol, 2, pp.127~137 (2001)
- Hynes NE, "ERBB receptors and cancer: the complexity of targeted inhibitors", Nat Rev Cancer, 5, pp.341~354 (2005)
- Slamon DJ, "Human breast cancer: correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- Wood ER, "A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells", Cancer Res, 64, pp.6652~6659 (2004)
- Geyer CE, "Lapatinib plus capecitabine for HER2-positive advanced breast cancer", N Engl J Med, 355, pp.2733~2743 (2006)
- Gomez HL, "Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer", J Clin Oncol, 26, pp.2999~3005 (2008)
- Vázquez-Martín A, "mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb)", Clin Transl Oncol, 11, pp.455~459 (2009)
- Berns K, "A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer", Cancer Cell, 12, pp.395~402 (2007)
- Esteva FJ, "PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer", Am J Pathol, 177, pp.1647~1656 (2010)
- Razis E, "Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer", Breast Cancer Res Treat, 128, pp.447~456 (2011)
- O’Brien NA, "Activated phosphoinositide 3-kinase", AKT signaling confers resistance to trastuzumab but not lapatinib, 2010, pp.9, 1489~1502
- Wang L, "PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib", BMC Cancer, 11, pp.248~ (2011)
- Dave B, "Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers", J Clin Oncol, 29, pp.166~173 (2011)
- Xia W, "Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers", Cancer Res, 67, pp.1170~1175 (2007)
- Eichhorn PJ, "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR", phosphatidylinositol 3-kinase inhibitor NVP-BEZ235, 2008, pp.68, 9221~9230
- Dufner A, "Ribosomal S6 kinase signaling and the control of translation", Exp Cell Res, 253, pp.100~109 (1999)
- Hay N, "Upstream and downstream of mTOR", Genes Dev, 18, pp.1926~1945 (2004)
- Noh WC, "Determinants of rapamycin sensitivity in breast cancer cells", Clin Cancer Res, 10, pp.1013~1023 (2004)
- Bärlund M, "Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis", J Natl Cancer Inst, 92, pp.1252~1259 (2000)
- van der Hage JA, "Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients", Br J Cancer, 90, pp.1543~1550 (2004)
- Kim EK, "Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer", Breast Cancer Res Treat, 126, pp.93~99 (2011)
- Kim EK, "Phosphorylated S6 kinase-1: a breast cancer marker predicting resistance to neoadjuvant chemotherapy", Anticancer Res, 33, pp.4073~4079 (2013)
- Kang S, "Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic", Proc Natl Acad Sci U S A, 102, pp.802~807 (2005)
- Noh WC, "Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables", Breast Cancer Res Treat, 110, pp.477~483 (2008)
- Fresno Vara JA, "PI3K", Akt signalling pathway and cancer, 2004, pp.30, 193~204
- Spector NL, "Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies", J Clin Oncol, 23, pp.2502~2512 (2005)
- McDermott M, "Mechanisms of resistance to lapatinib in HER2 positive breast cancer", pp.2012
- Vazquez-Martin A, "Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1", HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells, 2008, pp.19, 1097~1109
- Holz MK, "The role of S6K1 in ER-positive breast cancer", Cell Cycle, 11, pp.3159~3165 (2012)